STATE BOARD OF PHARMACY

Terminal distributor license exemptions (PARTIALLY VETOED)

- Adds exemptions from terminal distributor licensure related to nitrous oxide, medical oxygen, sterile water, and sterile saline.
- Would have added an exemption from terminal distributor licensure related to dog training in conjunction with law enforcement agencies (VETOED).

OBOT licensure eliminated

Eliminates the State Board of Pharmacy's licensure of office-based opioid treatment (OBOT) providers.

Terminal distributor license exemptions (PARTIALLY VETOED)

(R.C. 4729.541; conforming changes in R.C. 4729.51 and 4729.55)

The act adds the following to the list of exemptions from licensure as a terminal distributor of dangerous drugs:

- A person who possesses nitrous oxide for use as a direct ingredient in food under federal regulations or for testing or maintaining a plumbing or HVAC system;
- A person who possesses medical oxygen, sterile water, or sterile saline for direct patient administration or for installing or maintaining home medical equipment.

The Governor vetoed a provision that would have added an exemption for a person who possesses controlled substances and other dangerous drugs for dog training on behalf of, and under a written contract with, a law enforcement agency.

OBOT licensure eliminated

(Repealed R.C. 4729.553; Section 747.30; conforming changes in other sections)

The act eliminates State Board of Pharmacy licensure for office-based opioid treatment (OBOT). As defined under the repealed law, "office-based opioid treatment" was the treatment of opioid dependence or addiction using a controlled substance. The repealed law required a facility, clinic, or other location where a prescriber provides OBOT to more than 30 patients to hold a category III terminal distributor of dangerous drugs license with an OBOT classification, although various facilities and locations were exempt.

The act also provides that, in rescinding rules related to the repeal, the Pharmacy Board is not subject to review by the Common Sense Initiative Office, and the Board does not have to transmit a business impact analysis to the Office.

H.B. 33 Page | 494